Who Generates More Revenue? Regeneron Pharmaceuticals, Inc. or Cytokinetics, Incorporated

Regeneron vs. Cytokinetics: A Decade of Revenue Growth

__timestampCytokinetics, IncorporatedRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 2014469400002819557000
Thursday, January 1, 2015286580004103728000
Friday, January 1, 20161064070004860427000
Sunday, January 1, 2017133680005872227000
Monday, January 1, 2018315010006710800000
Tuesday, January 1, 2019268680007863400000
Wednesday, January 1, 2020558280008497100000
Friday, January 1, 20217042800016071700000
Saturday, January 1, 20229458800012172900000
Sunday, January 1, 2023753000013117200000
Monday, January 1, 202414202000000
Loading chart...

Unlocking the unknown

Revenue Showdown: Regeneron vs. Cytokinetics

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed Cytokinetics, Incorporated in terms of revenue. From 2014 to 2023, Regeneron's revenue surged by approximately 365%, peaking at over $13 billion in 2023. In contrast, Cytokinetics experienced a more modest growth, with revenue increasing by about 60% during the same period, reaching just over $10 million in 2023.

A Decade of Growth

Regeneron's revenue growth is a testament to its robust product pipeline and strategic market positioning. The company's revenue in 2021 alone was nearly 1,600% higher than Cytokinetics'. Despite Cytokinetics' innovative approaches, it remains a smaller player in the industry. This data highlights the stark contrast in financial performance between these two biotech firms, offering insights into their market strategies and future potential.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025